Ensign Group (ENSG) remains an attractive long-term investment as strong skilled-nursing occupancy, a favorable reimbursement and regulatory backdrop, and an active acquisition pipeline outweigh concerns about managed-care volumes, Oppenheimer said Wednesday in a report.

The stock trades at about 11 times estimated 2027 earnings before interest, taxes, depreciation, amortization and rent, below its five-year average of 14 times and 10-year average of 12 times, Oppenheimer said. The discount offers a buying opportunity because operating trends remain solid despite recent market "noise," the report said.

Same-store occupancy rose 190 basis points to a record 84.3% in Q1, while Ensign's 71 locations added since early 2025 and robust acquisition outlook provide further room for growth, the report said.

Ensign's strong cash flow and balance sheet should also help it continue acquisitions and withstand economic uncertainty, the report said.

Oppenheimer maintained its outperform rating on Ensign stock with a $210 price target.

Price: 169.21, Change: -1.66, Percent Change: -0.97